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Key papers in scientific literature sometimes bring a
definitive resolution to a long-awaited issue. Others may
be far less decisive but importantly implore us to question
the fitness of prevailing models. So it is that a paper in this
issue by F. Geissmann and colleagues (1), albeit subject to
some variety of interpretation, nevertheless compels us to
reexamine the widely accepted idea that migration of
Langerhans cells in response to inflammatory stimuli is
necessarily coupled to and follows from their maturation.
It is well established that in the steady-state Langerhans
cells turn over very slowly, but they can be mobilized en
masse by inflammatory or antigenic stimuli. In vitro and
in vivo, these inflammatory mediators have also been
observed to promote maturation, and Langerhans cells
that migrate from skin explants in culture usually display
a mature phenotype. In further agreement with the idea
that migration is linked with maturation is evidence that
molecules associated with migration, particularly CCR7
(2), are induced during Langerhans cell maturation (3).
Dendritic cell (DC) “maturation” is defined functionally
as the acquisition of potent immunogenic capacity.
Among DC biologists, this term signifies a particular
program of gene expression that typically includes the
upregulation of CD40, CD83, CD86, MHC products,
and other molecules associated with antigen presentation,
along with simultaneous induction of CCR7 (4). At the
same time, the ability to acquire and process antigen, a
feature that characterizes immature DCs, is downregulated.
Understanding the extent to which maturation and migration
are coupled lies at the heart of understanding how DCs
regulate T cell differentiation. If immature DCs promote
naive T cells to develop a tolerogenic phenotype (5), then one
is left wondering whether immature DCs traffic efficiently to
lymph nodes from the periphery. If they do, then what of the
belief that CCR7 is needed for DC migration to lymph nodes
and that CCR7 is expressed only by mature DCs? Clearly, the
fit of some pieces of the puzzle have to be reevaluated.
 
Evidence that Immature Langerhans Cells May Accumulate in
Lymph Nodes.
 
The paper by Geissmann et al. contains
two provocative observations that build on work the group
had previously published (6). First, the authors present
immunophenotypic analysis of human lymph node sections
taken from patients that suffer from dermatopathic
lymphadenopathy, a pathological disorder marked by
excessive accumulation of nonproliferative Langerhans
cells in lymph nodes that drain a chronically inflamed
skin site (7). These lymph nodes contain, not surprisingly,
abundant DCs that express low levels of E-cadherin and
what has been suggested to be a Langerhans cell–restricted
marker, Langerin. The striking observation is that none of
the Langerin
 
 
 
 E-cadherin
 
 
 
 CD1a
 
 
 
 cells (CD1a
 
 
 
 data
from reference 6) show expression of mature DC markers,
including CD86 and CD83. In contrast, neighboring DCs
that lack Langerin express CD86 and CD83. These data
suggest that Langerhans cells migrated to lymph nodes as
immature DCs, although several cautions to this interpretation
are applicable, as follows. (a) Although widely expressed by
Langerhans cells, Langerin is not restricted in expression
entirely to these epidermal DCs. For instance, Langerin is
expressed by dermal Langerhans cell precursors (8) and can
also be found in some other tissues (9). However, in
contrast to Langerhans cells and the lymph node cells
characterized by Geissmann and colleagues, dermal Lang-
erhans cell precursors do not express E-cadherin when
freshly isolated from skin (8). (b) Some of the results could
be specific to this particular inflammatory disease and not
broadly applicable to inflamed lymph nodes. (c) We cannot
be certain that the Langerin
 
 
 
 cells did not access lymph
nodes from the blood, given evidence that potential DC
precursors like plasmacytoid cells (10) and monocytes (11) can
enter inflamed lymph nodes by traversing high endothelial
venules (HEVs), rather than gaining access through afferent
lymph. However, that the disease occurs within the inflamed
skin and many of the Langerin
 
 
 
 CD83
 
 
 
 DCs were found
in or near afferent sinuses strongly suggests that the cells
recently arrived to the lymph node via afferent lymphatic
vessels rather than via HEVs. Furthermore, although a
small fraction of Langerin
 
 
 
 DCs have been spotted in
unlikely places for Langerhans cells, such as in spleen,
questioning the specificity of Langerin for LCs, one
would have to argue that none of the Langerin
 
 
 
 cells
observed by Geissmann et al. were derived from Langerhans
cells. This extreme view seems unlikely, and because
none of the Langerin
 
 
 
 cells showed signs of maturation,
it is reasonable to conclude that Langerhans cells and/or
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their dermal precursors accumulate within lymph nodes in
an immature state during this chronic inflammatory disease.
Even if this observation does not extend to all inflammatory
settings that involve Langerhans cell migration, the data
nevertheless imply that, at a basic level, Langerhans cell
maturation and migration may be quite separable events and
that maturation need not be strictly upstream of migration.
Informative animal models with regard to the study of
the phenotype of migratory lymph DCs are those in which
afferent lymph is sampled from cannulated thoracic ducts of
rats or sheep, after the animals have undergone surgical re-
section of intervening lymph nodes. These models demon-
strate the existence of at least two major phenotypes of DCs
within lymph, one of which is less mature, as exhibited, for
example, by less robust activity in stimulating proliferation
of allogeneic T cells (12). The flux of DC emigration via
lymph increases 8–15-fold in this model after systemic ad-
ministration of LPS (13), a well known DC maturation
stimulus. Much overlooked has been the finding that the
relative proportion of the less mature DC population does
not change after LPS treatment (13), suggesting that the mi-
gration-enhancing effects of LPS may not entirely stem
from its maturation-inducing properties
 
.
 
One, however, might argue that data on the behavior of
intestinal DCs may not be pertinent to Langerhans cells. In-
deed, even more so than for other potential sources of DCs,
Langerhans cells have been thought to be especially depen-
dent on maturation for migratory exit from the skin. This
study, however, suggests that in analogy to the diversity of
phenotypes observed in lymph-borne intestinal DCs, there
appears also to be diverse phenotypes or states of maturation
among migratory Langerhans cells in vivo. Thus, a more ac-
curate conclusion may be that, like intestinal DCs, Langer-
hans cell migration to lymph nodes includes a balance be-
tween immature and mature cells. Whereas all Langerin
 
 
 
cells in the lymph nodes studied by Geissmann et al. appear
immature, their own work (see Fig. 5 C, page 424) and that
of others (8, 9) indicate that fully mature Langerhans cells
may completely downregulate Langerin. Balancing the ap-
parent presence of the immature Langerin
 
 
 
 Langerhans cells
in the lymph nodes examined are the neighboring Langerin
 
 
 
mature DCs, some of which are likely to have at least partly
derived from Langerhans cells.
 
CCR7 and Migration of Immature DCs.
 
As mentioned
earlier, we have learned through experimentation that mo-
bilization of Langerhans cells to lymph nodes is triggered
by inflammatory mediators like the “maturation factors”
TNF-
 
 
 
 and IL-1
 
 
 
. Geissmann and colleagues, in a second
series of experiments, show us that TNF-
 
 
 
, at least under
some circumstances, can induce CCR7 without otherwise
causing maturation. The authors indicate that it is impossi-
ble to determine whether immature Langerin
 
 
 
 DCs ex-
pressed CCR7 in inflamed human lymph nodes, due to the
ubiquitous expression of CCR7 by neighboring lymph
node T cells. Therefore, they turn to an in vitro culture
system to generate cells resembling Langerhans cells. Here
they utilize monocytes cocultured in IL-4, GM-CSF, and
TGF-
 
 
 
1. The rationale for using TGF-
 
 
 
1 is reasonable,
given that Langerhans cells depend on this cytokine for de-
velopment (14) and the extent to which it promotes a
Langerhans cell phenotype, including expression of E-cad-
herin, Langerin, and the formation of Birbeck granules in
vitro. Geissmann et al. show that TGF-
 
 
 
1–generated
Langerhans cells do not become CD83
 
 
 
, nor express high
levels of CD86, when they are exposed to inflammatory
mediators like TNF-
 
 
 
 or even live 
 
Escherichia coli
 
. How-
ever, these triggers were sufficient to induce expression of
CCR7 and migratory responses to CCR7 chemotactic
ligands, suggesting that these Langerhans cells were ren-
dered able to migrate upon triggering by inflammatory
stimuli, but that they were incapable of maturing fully un-
less they were engaged by CD40 ligand (CD154).
The model that emerges provides a means by which im-
mune responses could be properly held in check, as it dimin-
ishes the idea that a simple inflammatory trigger sends nu-
merous Langerhans cells to the lymph node in a mature form
that could promote immune responses to undesirable targets
such as self-antigens. In this model, full maturation would be
at least somewhat restricted to the situation in which a DC
productively engages a T cell such that CD154 is induced on
the T cell and positively feeds back to drive activation of the
antigen-presenting cell. The widely reported immune-
enhancing power of anti-CD40 mAb mimetics of CD154
speak to the potency of such engagement.
However, it is difficult to accept the in vitro model and
interpretation in whole, because ex vivo–derived Langer-
hans cells mature much more easily than do these in vitro–
derived, TGF-
 
 
 
1–treated Langerhans cells. Furthermore, it
is important to note that withdrawal of TGF-
 
 
 
1 during the
late phases of the in vitro culture period permits substantial
Langerhans cell maturation in response to inflammatory
mediators (6), in contrast to the effects observed when this
cytokine is continuously present. Nonetheless, an impor-
tant observation arises from these experiments: namely, that
DCs can exist in a state/environment in which “matura-
tion” factors like TNF-
 
 
 
 are able to trigger the onset of a
migratory phenotype, including CCR7 expression, with-
out promoting full antigen presentation capacity. Thus, we
are left with a model in which immature DCs express
CCR7, suggesting that they may very well migrate via af-
ferent lymphatic vessels, a conclusion bolstered by the
pathologic evidence from inflamed lymph nodes.
An assumption that remains outstanding, however, is
the very fact that CCR7 is necessary for all DCs, regardless
of state of maturation, to migrate to afferent lymphatic
vessels. The relative scarcity of DCs in lymph nodes of
CCR7-deficient mice supports this notion but may be
misleading. It is quite possible that the lack of T cells in
the lymph nodes of CCR7
 
 
 
/
 
 
 
 mice secondarily depresses
the migration of Langerhans cells because DC mobiliza-
tion from skin is impaired in recombination activation
gene (RAG)2
 
 
 
/
 
 
 
 mice (15). Experiments are needed to
probe more thoroughly the role of CCR7 in DC migra-
tion, including the repetition of “FITC painting” contact 
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hypersensitivity experiments using skin transplants (16) in
which CCR7-deficient mice serve as skin transplant do-
nors and recipients are CCR7
 
 
 
/
 
 
 
 with normally devel-
oped lymph nodes. Other adoptive transfer approaches in
which CCR7
 
 
 
/
 
 
 
 circulating DC precursors (17) are trans-
ferred to normal hosts would also be extremely valuable
for assessing the conditions under which CCR7 may and
may not be essential for DC migration.
 
Nature’s Course: Stage of Inflammation Influences the Charac-
ter of Migratory DCs?
 
Even if we accept that it is likely
that the Langerin
 
 
 
 cells in the lymph node are Langerhans
cells, the possibility that these Langerhans cells may have
migrated to the lymph node in immature form should be
considered together with the alternative possibility that
the cells migrated in a mature state but downregulated co-
stimulatory molecules once in the lymph node. Consider-
ing that dermatopathic lymphadenopathy is a chronic
inflammatory disease, it is likely that the cytokine envi-
ronment within the tissue and that sampled by the drain-
ing lymph node includes a number of cytokines, but may
be particularly rich in cytokines that act to counterbalance
the positive feedback of proinflammatory cytokines. IL-10,
for example, has the capacity to downregulate costimula-
tory and MHC molecules on antigen-presenting cells,
even in the presence of proinflammatory mediators IL-1
and TNF-
 
 
 
. IL-10 is clearly a key cytokine in limiting in-
flammatory responses, since IL-10
 
 
 
/
 
 
 
 mice tend to suffer
from more robust inflammatory reactions than wild-type
counterparts.
A simple experiment using human skin explants, how-
ever, supports the argument and model laid forth by Geiss-
mann and colleagues suggesting that immature Langerhans
cells express functional CCR7 as they migrate from skin.
When human skin explants are cultured, a large fraction of
Langerhans cells exit the explants via dermal lymphatic ves-
sels (18). Most of these migratory cells are mature, since
many express, for example, surface CD83. All are CCR7
 
 
 
.
Addition of the proinflammatory cytokine IL-1
 
 
 
 increases
the degree of maturation in this population and somewhat
upregulates CCR7. Culturing the skin in IL-10 does not
block DC migration but leads to a population of emigres
that appear immature, and most lack CD83. These cells,
however, still express CCR7 and migrate to its ligand
CCL19 (unpublished data).
Another cytokine crucial to the regulatory control of
inflammatory reactions is TGF-
 
 
 
1. TGF-
 
 
 
1–deficient
mice succumb to massive inflammatory disease if this re-
sponse is not pharmacologically quelled. Geissmann et al.
employ TGF-
 
 
 
1 to generate Langerhans-like cells in
vitro, and leave TGF-
 
 
 
1 present in the cell cultures even
during steps in which maturation stimuli are added. Al-
though Langerhans cells require TGF-
 
 
 
1 for develop-
ment, it is not clear whether they are continuously pro-
ducing or are exposed to active forms of TGF-
 
 
 
1. Thus,
it is possible that the continuous use of TGF-
 
 
 
1 by Geiss-
mann and colleagues not only induces a Langerhans cell
phenotype but then also mimics later stages of inflamma-
tion when TGF-
 
 
 
1 would be present and operate to keep
the response in check (19). Thus, the cells that they study
may inadvertently, but interestingly, tell us something
about the effects of antiinflammatory cytokines not only
on Langerhans cells but on DCs in general—that they
prevent maturation but do not block migration. If so,
then a new version of the model develops in which the
cytokine profile of an advanced inflammatory response
containing molecules like IL-10 and TGF-
 
 
 
1 promote
the transit of immature DCs to the lymph node, which in
turn may participate in downregulating immune re-
sponses. At earlier stages of an inflammatory response,
when antiinflammatory cytokine levels may be very low,
Langerhans cells and other DCs may be more likely to be
found in mature form. Although dermatopathic lymphad-
enopathy is an inflammatory response that apparently does
not resolve properly, many of the cytokine networks that
normally operate in late stages of inflammation may nev-
ertheless be present. Future research using animal models
in which the state of maturation of migrating Langerhans
cells at different phases of an inflammatory response will
be required to distinguish between the intriguing new
models raised by this study.
 
Langerhans Cells and Contact Sensitivity: An Uncertain
Role?
 
While considering that Langerhans cells may arrive
to the lymph node in an immature state, it seems reason-
able to review the evidence that Langerhans cells per se
are required for induction of contact sensitivity, a proto-
typical immune response initiated from the skin surface.
After epicutaneous application of FITC, it is clear that
skin-derived FITC
 
 
 
 DCs migrate to the lymph node and
mediate contact sensitivity (16, 20), as particularly evident
from adoptive transfer of lymph node FITC
 
 
 
 DCs as me-
diators of contact sensitivity. However, it is not certain
that all of the transferred cells derive from Langerhans
cells, since FITC
 
 
 
 migratory DCs are heterogeneous with
regard to a number of markers, including differing levels
of CD11c (21). Although Sato and colleagues present evi-
dence that FITC
 
 
 
 cells mainly derive from the epidermis,
they show that dermal cells which express a lectin called
MMGL are required for the onset of contact hypersensi-
tivity (22). They initially described these cells as macro-
phages, but they may also be DCs (23, 24). The possibility
that these cells, rather than Langerhans cells, are the pri-
mary inducers of contact sensitivity and that Langerhans
cells play a more regulatory role cannot be eliminated. In
conclusion, it is perhaps sobering to reflect on the reality
that the most well characterized migratory population of
DCs, Langerhans cells, still harbors so many secrets.
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